康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300601 康泰生物

已收盘 05-17 15:00:00

{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":19.86,"timestamp":1715929395000,"preClose":19.62,"halted":0,"volume":8137748,"delay":0,"floatShares":881000000,"shares":1117000000,"eps":0.6356,"marketStatus":"已收盘","marketStatusCode":5,"change":0.24,"latestTime":"05-17 15:00:00","open":19.59,"high":19.94,"low":19.51,"amount":161000000,"amplitude":0.0219,"askPrice":19.86,"askSize":201,"bidPrice":19.85,"bidSize":130,"shortable":0,"etf":0,"ttmEps":0.6356,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":19.62,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":21.58,"lowLimit":17.66,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116916640,"pbRate":2.41,"roa":"--","roe":"0.56%","epsLYR":0.77,"committee":-0.173641,"marketValue":22182000000,"floatMarketCap":17504000000,"peRate":31.246068,"changeRate":0.0122,"turnoverRate":0.0092,"status":0},"requestUrl":"/m/hq/s/300601/","defaultTab":"news","newsList":[{"id":"2435256689","title":"5月15日康泰生物发生3笔大宗交易 成交金额1929.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435256689","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435256689?lang=zh_cn&edition=full","pubTime":"2024-05-15 16:40","pubTimestamp":1715762446,"startTime":"0","endTime":"0","summary":"证券之星消息，5月15日康泰生物发生大宗交易，交易数据如下：近三个月该股共发生6笔大宗交易，合计成交1.55万手。该股近期无解禁股上市。截至2024年5月15日收盘，康泰生物(300601)报收于19.72元，下跌3.14%，换手率1.1%，成交量9.68万手，成交额1.93亿元。该股最近90天内共有9家机构给出评级，买入评级9家；过去90天内机构目标均价为30.66。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500029429.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433445809","title":"5月6日康泰生物涨5.20%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433445809","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433445809?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:38","pubTimestamp":1714984715,"startTime":"0","endTime":"0","summary":"证券之星消息，5月6日康泰生物涨5.20%，收盘报21.25元，换手率2.19%，成交量19.28万手，成交额4.07亿元。重仓康泰生物的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级7家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为3.67亿元，最新净值0.6771，较上一交易日下跌0.15%，近一年下跌25.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600015298.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431465190","title":"康泰生物（300601）4月26日主力资金净买入4079.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431465190","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431465190?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:12","pubTimestamp":1714353170,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月26日收盘，康泰生物报收于20.75元，上涨7.01%，换手率2.04%，成交量18.01万手，成交额3.62亿元。近5日资金流向一览见下表：康泰生物融资融券信息显示，融资方面，当日融资买入7601.19万元，融资偿还2297.71万元，融资净买入5303.48万元。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900002130.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430279741","title":"康泰生物(300601)3月31日股东户数6.61万户，较上期减少1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430279741","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430279741?lang=zh_cn&edition=full","pubTime":"2024-04-27 17:19","pubTimestamp":1714209571,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康泰生物披露，截至2024年3月31日公司股东户数为6.61万户，较12月31日减少961.0户，减幅为1.43%。在生物制品行业个股中，康泰生物股东户数高于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.33万户。从股价来看，2023年12月31日至2024年3月31日，康泰生物区间跌幅为19.37%，在此期间股东户数减少961.0户，减幅为1.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700025595.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430784069","title":"图解康泰生物一季报：第一季度单季净利润同比减73.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430784069","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430784069?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:18","pubTimestamp":1714155539,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物2024年一季报显示，公司主营收入4.52亿元，同比下降39.65%；归母净利润5406.59万元，同比下降73.69%；扣非净利润1438.38万元，同比下降92.42%；负债率35.95%，投资收益0.0万元，财务费用461.1万元，毛利率84.07%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700004018.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430279014","title":"康泰生物(300601.SZ)发布一季度业绩，净利润5406.59万元，同比减少73.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430279014","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430279014?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:44","pubTimestamp":1714135472,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布2024年第一季度报告，公司于报告期内实现营业收入4.52亿元，同比减少39.65%;归属于上市公司股东的净利润5406.59万元，同比减少73.69%;归属于上市公司股东的扣除非经常性损益的净利润1438.38万元，同比减少92.42%;基本每股收益0.05元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112282.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430244345","title":"4月26日康泰生物涨7.01%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430244345","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430244345?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:25","pubTimestamp":1714119951,"startTime":"0","endTime":"0","summary":"证券之星消息，4月26日康泰生物涨7.01%，收盘报20.75元，换手率2.04%，成交量18.01万手，成交额3.62亿元。重仓康泰生物的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级6家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为3.67亿元，最新净值0.6503，较上一交易日上涨0.31%，近一年下跌27.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600035324.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430446822","title":"康泰生物涨7.01%，德邦证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430446822","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430446822?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:25","pubTimestamp":1714119946,"startTime":"0","endTime":"0","summary":"今日康泰生物涨7.01%，收盘报20.75元。2024年3月10日，德邦证券研究员陈铁林发布了对康泰生物的研报《发布“质量回报双提升”方案，看好公司长期发展潜力》，该研报对康泰生物给出“买入”评级。研报中预计23-25年业绩分别为8.9/11.4/13.8亿元，对应当前PE分别为29/23/19倍，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为15.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600035318.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427584726","title":"康泰生物(300601.SZ)：水痘减毒活疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2427584726","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427584726?lang=zh_cn&edition=full","pubTime":"2024-04-16 18:49","pubTimestamp":1713264540,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(简称“民海生物”)今日收到国家药品监督管理局签发的《药品注册证书》，药片名称为：水痘减毒活疫苗。公告显示，水痘减毒活疫苗系用水痘-带状疱疹病毒接种于人二倍体细胞，经培养，收获病毒液，加入适宜稳定剂冻干制成。该疫苗适用于12月龄以上健康水痘易感人群，接种后可刺激机体产生抗水痘-带状疱疹病毒的免疫力，用于预防水痘。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarzpww9567355.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarzpww9567355.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2402685974","title":"康泰生物扭亏2023年预盈9.5亿 疫苗投入减少研发费9个月降38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2402685974","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2402685974?lang=zh_cn&edition=full","pubTime":"2024-01-11 07:58","pubTimestamp":1704931080,"startTime":"0","endTime":"0","summary":"　　2022年净利短暂亏损后，康泰生物2023年业绩回正。　　1月9日，康泰生物披露2023年业绩预告，公司预计实现归母净利润约8.5亿至9.5亿元，同比扭亏为盈。　　而且由于新冠疫苗三期临床投入减少，2023年前三季度公司的研发费用大幅缩减。　　同一天，康泰生物还公布了董事会提议向下修正可转换公司债券转股价格的公告，这是公司自2021年7月15日可转债发行以来第三次下修。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-01-11/doc-inacccqh3459643.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-01-11/doc-inacccqh3459643.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2402145415","title":"康泰生物预计去年净利最高超9亿元 同比大幅扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2402145415","media":"证券日报 ","top":-1,"share":"https://www.laohu8.com/m/news/2402145415?lang=zh_cn&edition=full","pubTime":"2024-01-11 00:23","pubTimestamp":1704903780,"startTime":"0","endTime":"0","summary":"本报记者 李雯珊见习记者 刘晓一1月10日，康泰生物发布的业绩预告显示，公司预计2023年归母净利润为8.5亿元至9.5亿元，与上年同期亏损1.33亿元相比，实现大幅扭亏。扣非净利润为7亿元至8.3亿元，较上年同期增长483.04%至554.17%。康泰生物主要从事人用疫苗的研发、生产和销售。2023年12月28日，公司发布公告称，子公司生产的冻干人用狂犬病疫苗已获得批签发证明。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-01-11/doc-inacansp6030336.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-01-11/doc-inacansp6030336.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2390491352","title":"康泰生物(300601.SZ)拟授出1000万份股票期权、2000万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2390491352","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2390491352?lang=zh_cn&edition=full","pubTime":"2023-12-11 22:22","pubTimestamp":1702304520,"startTime":"0","endTime":"0","summary":"康泰生物披露2023年股票期权与限制性股票激励计划(草案)，公司拟向激励对象授予的股票期权数量为1000万份，其中首次授予808.40万份，预留191.60万份;拟向激励对象授予限制性股票2000万股，其中首次授予1663.70万股，预留336.30万股。此外，本激励计划有效期为自股票期权/限制性股票首次授予之日起至激励对象获授的所有股票期权完成行权或注销和所有限制性股票完成归属或作废失效之日止，最长不超过60个月。股市回暖，抄底炒股先开户！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-11/doc-imzxseur1704280.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-11/doc-imzxseur1704280.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2386919115","title":"康泰生物：四价流感病毒裂解疫苗正式开启Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2386919115","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2386919115?lang=zh_cn&edition=full","pubTime":"2023-11-28 18:20","pubTimestamp":1701166800,"startTime":"0","endTime":"0","summary":"康泰生物公告，公司研发的四价流感病毒裂解疫苗已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。               \n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-11-28/doc-imzweitu7287116.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-11-28/doc-imzweitu7287116.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦101","stockEarnings":[{"period":"1week","weight":-0.0457},{"period":"1month","weight":-0.0289},{"period":"3month","weight":-0.1581},{"period":"6month","weight":-0.3371},{"period":"1year","weight":-0.3069},{"period":"ytd","weight":-0.2685}],"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","perCapita":"13342股","boardName":"医药制造业","registeredCapital":"111691万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　深圳康泰生物制品股份有限公司主营业务为人用疫苗的研发、生产和销售。公司的主要产品为免疫规划疫苗、非免疫规划疫苗。公司拥有专利70余项，已上市及获批紧急使用的产品10种，在研品种30余项，基本涵盖全球重磅疫苗品种，其中，公司自主研发的用于乙肝疫苗无应答特殊人群的“60µg重组乙型肝炎疫苗（酿酒酵母）”和“双载体13价肺炎球菌多糖结合疫苗”属全球首创。","serverTime":1716149309529,"listedPrice":3.29,"stockholders":"66057人(较上一季度减少1.43%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}